Zentalis Pharmaceuticals, Inc. (ZNTL)

11,77 -0,80 (-6,36%) Alla chiusura: 04:00PM EDT

Zentalis Pharmaceuticals, Inc.

1359 Broadway
Suite 1710
New York, NY 10018
United States
212 433 3791
https://zentalis.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 124

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Kimberly Lynn Blackwell M.D.	CEO & Director	1,12M	N/D	1970
Mr. Cameron S. Gallagher M.B.A.	Co-Founder, President, Interim CFO, Treasurer & Director	767,69k	N/D	1971
Ms. Andrea Paul J.D.	Chief Legal Officer & Corporate Secretary	668,2k	N/D	1982
Mr. Vincent Vultaggio	VP of Finance & Interim Principal Accounting Officer	N/D	N/D	1983
Dr. Mark Lackner Ph.D.	Chief Scientific Officer	N/D	N/D	1968
Dr. Diana F. Hausman M.D.	Chief Medical Officer & Director	N/D	N/D	1963
Ms. Kimberly Freeman	Chief Strategy Officer	N/D	N/D	N/D
Dr. Kyle Rasbach Ph.D., Pharm.D.	Chief Business Officer	N/D	N/D	1980
Dr. Adrian Jubb M.D., Ph.D.	Executive Vice President of Clinical Development	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Governance aziendale

L'ISS Governance QualityScore di Zentalis Pharmaceuticals, Inc. al 1 aprile 2024 è 10. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 5; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.